Prenetics Global Ltd - PRE Enterprise Value-to-Revenue Multiple

Public company logo of Prenetics Global Ltd (PRE)

Prenetics Global (PRE) strives for leadership in the Asian segment of early diagnostics and affordable genetic screening. The EV-to-annual-revenue multiple demonstrates a pivot driven by the implementation of AI DNA analysis and portable systems. The stability of the geneticists' and developers' workforce also supports this trend. The value 536.67 represents the current level of the metric determining the business value relative to its revenues, excluding debt.

PRE (Prenetics Global Limited) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

PRE (Prenetics Global Limited): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental valuation:Prenetics Global Limited PRE
Manufactured product of Prenetics

The EV/Sales metric determines the business value, including net debt, relative to generated revenue, excluding the impact of leverage. For Prenetics Global (PRE), this indicator reflects market expectations regarding the commercialization of early cancer detection systems. By analyzing this EV/Sales chart, an investor can see the capitalization trend against the scaling of liquid biopsy. High values confirm technological maturity but signal a risk of overpayment.

Competitor analysis for Prenetics Global

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue